FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 353:1091-1093 September 15, 2005 Number 11 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

Should physicians sell their expertise and knowledge about clinical research to Wall Street? In recent months, financial relationships between some physicians and the investment industry have come under scrutiny.^1,2,3 Physicians have been paid to provide investors with general information about therapeutic problems, the mechanism of action of drugs, and the regulatory process. Some of these activities may ultimately have benefit to society. However, some physicians have also allegedly been paid to reveal specific confidential data.

In August 2005, the Seattle Times reported that it had found "at least 26 cases in which doctors have leaked confidential and critical details of . . . [Full Text of this Article]

Source Information

Dr. Steinbrook is a national correspondent for the Journal.

This article has been cited by other articles:

• Steensma, D. P. (2008). Investment analysts and the American Society of Hematology. Blood 112: 29-33 [Abstract] [Full Text]  
• Wells, R. J. (2008). Secrecy and Integrity in Clinical Trials. JCO 26: 680-682 [Full Text]  
• Berlin, J., Bruinooge, S. S., Tannock, I. F. (2007). Ethics in Oncology: Consulting for the Investment Industry. JCO 25: 444-446 [Abstract] [Full Text]  
• The American Society of Clinical Oncology, (2007). Interactions With the Investment Industry: Practical and Ethical Implications. JCO 25: 338-340 [Full Text]